Key Markets Update

NZX/ASX Announcement

20 May 2024
TruScreen – Key Markets Update

Highlights

• TruScreen installed in major hospital in Jiangsu, China
• Collaboration with PT Mursmedic in Indonesia with product registration in progress
• MOH Uzbekistan evaluating TruScreen for national screening program
• TruScreen partnering with Phillips Pharma for expansion in Kenya, Nigeria, Uganda, Ghana
and Tanzania
• Further progress in Vietnam, Saudi Arabia and Mexico
TruScreen Group Limited (NZX/ASX:TRU) is pleased to provide an update of its key markets and
key target markets. TruScreen continues to make steady progress in its global commercialisation.
China continues to be TruScreen’s key focus, however there are some exciting opportunities in a
number of new markets as outlined below.

China
Number of Women of Screening Age: 476,599,793*
In April, TruScreen’s distributor in China, Beijing Siweixiangtai Tech Ltd. Co (SWXT), commenced a
major initiative in Jiangsu province, located in Eastern China with a population of 85 million people.
TruScreen was installed and key staff trained in the Affiliated Hospital of Nantong University, a major
hospital in North Jiangsu. The hospital’s head of Obstetrics and Gynaecology is a Key Opinion Leader
in this region. SWXT’s local distributor estimates that this hospital will achieve a 1,000 SUS per month
pull through, bringing it into the top 5 TruScreen sites globally.
SWXT reinforced the inclusion of TruScreen in the Chinese Society of Colposcopy and Cervical
Pathology (CSCCP) guidelines by sponsoring their annual conference held in Tianjin on 10 to 12 May
2024. The conference was attended by more than 1,000 gynaecologists from around the country.
The sponsorship is an extension of SWXT’s work with CSCCP to ‘normalise’ the use of TruScreen in
cervical cancer screening.
Sales of our disposable Single Use Sensors (SUS) in China continue to grow, with monthly sales in
April growing 3.6% month on month.
We have also completed our price review in China to reflect our increased cost pressures.
Indonesia
Number of Women of Screening Age: 95,961,293*
TruScreen, with the support of the local Austrade office, is making strides in Indonesia. Indonesia
sees over 36,000 women diagnosed with cervical cancer annually. PT Mursmedic
(https://mursmedic.com/
) has commenced the product registration process for TruScreen in
Indonesia. Based in Jakarta, Mursmedic’s other clients include a suite of major medical device

manufacturers such as Fisher and Paykel Healthcare, Cook, Nanosonics, Stryker
and ThermoFisher Scientific. A key reference site in Jakarta has been identified and installation will
occur as soon as registration is completed.
Uzbekistan
Number of Women of Screening Age: 11,617,411*
The Ministry of Health in Uzbekistan is evaluating TruScreen as a technology to deliver a part of the
Uzbekistan National Screening Solution for Cervical Cancer. This program is a first for Uzbekistan
and being selected would be a transformative opportunity for TruScreen, not just in Uzbekistan but
also to serve as a reference site for other neighbouring Central Asian countries.
Kenya
Number of Women of Screening Age: 17,723,012*
TruScreen is currently in the process of registration in Kenya through our logistics partner, Phillips
Pharma Group ( https://phillipspharma.group/
). Phillips Pharma is one of the most trusted partners in
Sub Saharan Africa supporting many of the major multinational Pharma and Medical Device
companies, as well as Government and NGO clients. Leveraging our proven capability as a screening
solution for women in Zimbabwe, TruScreen will partner with Phillips Pharma first in Kenya, and then
to expand to other countries within their footprint, including Nigeria, Uganda, Ghana and Tanzania.
Mexico
Number of Women of Screening Age: 45,983,174*
TruScreen has recently gained regulatory approval (Cofepris) for TruScreen to be used as a cervical
cancer screening system for public hospitals. Our distributor Sunbird S.A de C.V is leveraging this
approval to gain access to key influencing hospitals in the capital and as a result we have this month
shipped 9 devices to Mexico.
Vietnam
Number of Women of Screening Age: 35,887,201*
Since our inclusion in the Vietnamese Ministry of Health Technical List, significant strides have been
made to streamline the approval process for our medical technology. Our distributor, Gorton Health
Services (GHS), has targeted approval in 64 major public hospitals. GHS is supporting this initiative
to drive the adoption in these targeted hospitals by showcasing TruScreen at the Vietnam National
Gynaecologic Conference on May 24th. Installation into the first key reference sites will commence
mid to late 2024, with a projected peak installation into hospitals in 2025.
Saudi Arabia:
Number of Women of Screening Age: 10,994,061*
Following early success in the private health system, including gaining private health insurance
reimbursement and installation in key reference centres, our distributor Bettalife is working to have
TruScreen accepted into the public healthcare system. Similar to Uzbekistan, TruScreen is being
considered as a component, alongside other technologies, for the National Screening solution for the
7 million women under public health care in Saudi Arabia.

Poland
Number of Women of Screening Age: 13,036,977*
Poland continues to face significant challenges with cervical cancer. TruScreen is working with the
Mother and Child Institute and has identified both private and public hospitals as the first to move from
Liquid Based Cytology to TruScreen. TruScreen is shortly entering the hospital validation phase with
commercial sales following the successful completion of this evaluation.
North Macedonia
Number of Women of Screening Age: 719,627*
TruScreen is currently undergoing evaluation by a local distributor who operates a Medical Clinic in
North Macedonia. When successful, TruScreen will replace Pap Smear in the clinic. This clinic will
serve as a base for demonstration and training for future customers in south eastern Europe. This
potential partnership marks a significant milestone as it would be TruScreen's first partner who is both
a distributor and a key reference centre.
*All population figures are for women aged 15-64 years as detailed in the World Fact Book :
https://www.cia.gov/the-world-factbook/


Martin Dillon, CEO of TruScreen said “I am excited with the opportunities that TruScreen now has.

Many of these markets have taken us many years to gain meaningful access and TruScreen is now
gaining momentum which should deliver much improved results in the year ahead.”


This announcement has been approved by the Board.

ENDS
For more information, visit www.truscreen.com
or contact:
Marty Dillion
Chief Executive Officer
martindillon@truscreen.com

Guy Robertson
Chief Financial Officer
guyrobertson@truscreen.com

About TruScreen:

TruScreen Group Limited (NZX/ASX: TRU) is a medical device company that has developed and
manufactures an AI-enabled device for detecting abnormalities in the cervical tissue in real-time via
measurements of the low level of optical and electrical stimuli.
TruScreen’s cervical screening technology enables cervical screening, negating sampling and
processing of biological tissues, failed samples, missed follow-up, discomfort, and the need for costly,
specialised personnel and supporting laboratory infrastructure.
The TruScreen device, TruScreen Ultra
®
, is registered as a primary screening device for cervical
cancer screening.
The device is CE Marked/EC certified, ISO 13485 compliant and is registered for clinical use with the
TGA (Australia), MHRA (UK), NMPA (China), SFDA (Saudi Arabia), Roszdravnadzor (Russia), and
COFEPRIS (Mexico). It has Ministry of Health approval for use in Vietnam, Israel, Ukraine, and the
Philippines, among others and has distributors in 29 countries. In 2021, TruScreen established a
manufacturing facility in China for devices marketed and sold in China.
TruScreen technology has been recognised in CSCCP’s (Chinese Society for Colposcopy and
Cervical Pathology) China Cervical Cancer Screening Management Guideline.
TruScreen has been recognised in a China Blue Paper “Cervical Cancer Three Stage Standardized
Prevent and Treatment” published on 28 April 2023.
In financial year 2023 alone, over 140000
1
examinations have been performed
with TruScreen device. To date, over 200 devices have been installed and used in China, Vietnam,
Mexico, Zimbabwe, Russia, and Saudi Arabia. TruScreen’s vision is “A world without the cervical
cancer”
©
.
To learn more, please visit: www.truscreen.com/.
1
Based on Single Use Sensor sales.

Glossary:
Pap smear (the Papanicolaou smear) test involves gathering a sample of cells from the cervix, with
a special brush. The sample is placed on a glass slide or in a bottle containing a solution to
preserve the cells. Then it is sent to a laboratory for a pathologist to examine under a
microscope. https://www.cancer.net/navigating-cancer-care/diagnosing-cancer/tests-and-
procedures/pap-test
LBC (the liquid-based cytology) test, transfers a thin layer of cells, collected with a brush from the
cervix, onto a slide after removing blood or mucus from the sample. The sample is preserved so
other tests can be done at the same time, such as the human papillomavirus (HPV)
test https://www.cancer.net/cancer-types/cervical-cancer/diagnosis

HPV (human papilloma virus) test is done on a sample of cells removed from the cervix, the same
sample used for the Pap test or LBC. This sample is tested for the strains of HPV most commonly
linked to cervical cancer. HPV testing may be done by itself or combined with a Pap test and/or
LBC. This test may also be done on a sample of cells which a person can collect on their own.
https://www.cancer.net/cancer-types/cervical-cancer/screening-and-prevention


Sensitivity and specificity mathematically describe the accuracy of a test which reports the
presence or absence of a condition. If individuals who have the condition are considered "positive"
and those who don't are considered "negative", then sensitivity is a measure of how well a test can
identify true positives and specificity is a measure of how well a test can identify true negatives:
• Sensitivity (true positive rate) is the probability of a positive test result, conditioned on
the individual truly being positive.
• Specificity (true negative rate) is the probability of a negative test result, conditioned on
the individual truly being negative (Sensitivity and specificity – Wikipedia).
For more information about the cervical cancer and cervical cancer screening in New Zealand and
Australia, please see useful links:
New Zealand: National Cervical Screening Programme | National Screening Unit (nsu.govt.nz)

Australia: Cervical cancer | Causes, Symptoms & Treatments | Cancer Council